Substance Abuse Screening in PAC with GIA®
Substance abuse can significantly impede the recovery process in Post-Acute Care (PAC) settings. [GIA®](/gia), integrated with [digitalhumanOS™](/platform), offers a discreet and effective method for substance abuse [screening](/screening).
Key Facts
- Substance abuse can hinder recovery in PAC.
- Early intervention improves treatment success.
- GIA® facilitates discreet substance abuse screening.
Substance abuse can significantly impede the recovery process in Post-Acute Care (PAC) settings. GIA®, integrated with digitalhumanOS™, offers a discreet and effective method for substance abuse screening. Early intervention is crucial for improving treatment outcomes and supporting patients on their path to recovery.
PAC Challenges
Substance abuse can complicate rehabilitation and increase the risk of complications in PAC.
GIA®'s Solution
GIA® provides a non-judgmental and confidential screening process via digitalhumanOS™.
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.
Streamlined Process
Integrates seamlessly into existing PAC workflows, minimizing disruption to patient care.
Improved Outcomes
Early intervention can lead to better treatment adherence and improved recovery outcomes.
Conclusion
Utilizing GIA® for substance abuse screening in PAC enables case managers to provide comprehensive and supportive care, promoting successful recovery and preventing relapse.
Sources & References
- Behavioral Health Assessment Using Vocal Biomarkers. 2026.
- Audio-based Detection of Anxiety and Depression via Vocal Biomarkers. 2023.
- Scienza Health internal validation: 46 conditions screened, 2,500+ speech biomarkers.
David Kaiser is the Founder and CEO of Scienza Health. He leads the development of GIA® and digitalhumanOS™, a clinically validated speech biomarker platform that screens for 46 cognitive and neurological conditions in under 5 minutes.
This content is intended for informational purposes and does not constitute medical advice. Editorially reviewed by David Kaiser, CEO of Scienza Health, for accuracy in post-acute care operations.
Frequently Asked Questions
Is it confidential?
Strictly confidential, HIPAA compliant.
Is it easy to administer?
User-friendly and efficient.
What happens after screening?
Referral to appropriate resources.
The Clinical Signal
Hear the latest episode on clinical AI screening in post-acute care.